N2001-03: CEP-701 in Treating Young Patients With Recurrent or Refractory High-Risk Neuroblastoma

NCT00084422 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

47

Enrollment

OTHER

Sponsor class

Conditions

Neuroblastoma

Interventions

DRUG: lestaurtinib

Sponsor

New Approaches to Neuroblastoma Therapy Consortium

Collaborators

[object Object]